The highlights of the recent American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting tended to be data for approved drugs and therapies in later-stage development that back up previously reported efficacy or provide assurances about safety in rheumatoid and psoriatic arthritis and other autoimmune diseases.
Those kinds of data are important for prescribers and patients, offering points of differentiation in indications with a growing number...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
